ReviewArthritis research & therapy2011
The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.
Review in Arthritis research & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature.Arthritis & rheumatology (Hoboken, N.J.) · 2024Trial
- Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2021Trial
- A Pilot Study to Determine if Vitamin D Repletion Improves Endothelial Function in Lupus Patients.The American journal of the medical sciences · 2015Trial
- Endothelial cells modulate immune cell responses during atherosclerosis.Trends in immunology · 2026Review
- Immunophenotypes and prognosis in autoimmune cardiovascular disease: a narrative review from clonal hematopoiesis to myocarditis, microvascular angina, and HFpEF.Annals of medicine and surgery (2012) · 2026Review
- Acute Myocardial Infarction Secondary to Triple Vessel Coronary Artery Disease in a 31-year-old Female with Systemic Lupus Erythematosus: Case Report and Review of Literature.Acta medica Philippina · 2026Article
- Cardiac Sarcoma Mimicking Libman-Sacks Endocarditis in a Patient with Systemic Lupus Erythematosus (SLE): A Case Report and Literature Review.Journal of clinical medicine · 2024Review
- Myeloid cell-derived interleukin-6 induces vascular dysfunction and vascular and systemic inflammation.European heart journal open · 2024Article
- Nutritional Approaches to Modulate Cardiovascular Disease Risk in Systemic Lupus Erythematosus: A Literature Review.Nutrients · 2023Review
- In-stent restenosis is associated with proliferative skin healing and specific immune and endothelial cell profiles: results from the RACHEL trial.Frontiers in immunology · 2023Article
- Causes of Death Among Individuals With Systemic Lupus Erythematosus by Race and Ethnicity: A Population-Based Study.Arthritis care & research · 2023Article
- Non-Traditional Pro-Inflammatory and Pro-Atherosclerotic Risk Factors Related to Systemic Lupus Erythematosus.International journal of molecular sciences · 2022Review
- Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures.TH open : companion journal to thrombosis and haemostasis · 2022Review
- Spontaneous Coronary Artery Dissection With Systemic Lupus Erythematosus.Ochsner journal · 2022Article
- Vascular Inflammation in Mouse Models of Systemic Lupus Erythematosus.Frontiers in cardiovascular medicine · 2022Article
- Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE.EBioMedicine · 2021Article
- Urinary biomarkers in lupus nephritis.Journal of translational autoimmunity · 2020Review
- Progression of atherosclerosis versus arterial stiffness with age within and between arteries in systemic lupus erythematosus.Rheumatology international · 2019Article
- Critical limb ischemia in a patient with systemic lupus erythematosus: a case report.Journal of medical case reports · 2019Review
- Evaluation of Impact of Interferon-Induced Helicase C Domain-Containing Protein 1 Gene in Egyptian Systemic Lupus Erythematosus Patients and its Relationship With Vascular Manifestations of the Disease.Archives of rheumatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Patients with systemic lupus erythematosus have up to a 50-fold increased risk of developing atherosclerotic cardiovascular disease. Recent advances in the etiology of vascular damage in this disease stress the interplay of lupus-specific inflammatory factors with traditional cardiac risk factors, leading to increased endothelial damage. This review analyzes the putative role that immune dysregulation and lupus-specific factors may play in the pathogenesis of premature vascular damage in this disease. The potential role of various cytokines, in particular type I interferons, in the development of accelerated atherosclerosis is examined. Potential therapeutic targets are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.